Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.39 |
| ▸ | PLK1 | P53350 | 5/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10516793 | 0.81 | BRD4 (0.33) | BRD4PLK1CREBBPCCNCCDK8 | |
| SCHEMBL300079 | 0.79 | HCAR2 (0.35) | — | |
| SCHEMBL15555699 | 0.79 | PARP1 (0.30) | — | |
| SCHEMBL19358702 | 0.77 | ALDH1A1 (0.45) | TP53SMN1; SMN2 | |
| SCHEMBL25354020 | 0.77 | SLC7A5 (0.44) | — | |
| SCHEMBL25354014 | 0.77 | SLC7A5 (0.44) | — | |
| SCHEMBL20571366 | 0.76 | CREBBP (0.39) | BRD4PLK1CREBBPCCNCCDK8 | |
| SCHEMBL163859 | 0.76 | CREBBP (0.39) | BRD4PLK1CREBBPCCNCCDK8 | |
| SCHEMBL27045145 | 0.72 | — | — | |
| SCHEMBL19868327 | 0.70 | CREBBP (0.35) | BRD4PLK1CREBBPCCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | BRD4 1323/4885PLK1 528/4885CREBBP 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.